Best of IGCS 2022 Annual Global Meeting-How do we define non-eligible for Platinum in Ovarian Cancer: Impact of prior therapies and novel strategies for treatment

How do we define non-eligible for Platinum in Ovarian Cancer: Impact of prior therapies and novel strategies for treatment - Industry Symposium by Novocure

Back to course

Video Transcription

Video Summary

The video transcript is a symposium on non-eligibility for platinum-based therapy in ovarian cancer. The symposium is sponsored by Novacure and the Ju-Ju Foundation. The panel of speakers includes Dr. David O'Malley, Dr. Bradley Monk, Dr. Kathleen Moore, Dr. Vonda Salutari, Dr. Isabel Rae-Cucard, and Dr. Ahmed Oza. The symposium aims to increase knowledge on defining non-eligibility for platinum-based therapy, impact of prior therapies, PARP resistance, and novel strategies for treatment. <br /><br />Dr. Monk discusses the use of platinum-based therapy, definition of platinum-resistant recurrent ovarian cancer, and the role of bevacizumab in treatment. Dr. Rae-Cucard presents her talk on PARP resistance, discussing mechanisms and potential factors that can predict resistance to PARP inhibitors. The video also mentions ongoing clinical trials exploring combination therapies and various strategies, such as targeting the replication fork and using gemcitabine-induced replication stress.<br /><br />Other strategies discussed include the use of a PA3 kinase inhibitor to induce a BRCA-like phenotype, downregulate proteins involved in DNA damage response, and the potential of novel therapies such as TAS-102 and TTF. The need for further research and biomarker-driven studies is emphasized to better understand and treat platinum-resistant ovarian cancer.<br /><br />In summary, the video explores different avenues of investigation to address the unmet needs in platinum-resistant ovarian cancer, including combination therapies, targeting replication fork, and novel therapies. The importance of further research and biomarker-driven studies is highlighted throughout the symposium.

Keywords

symposium

non-eligibility

platinum-based therapy

ovarian cancer

Novacure

Ju-Ju Foundation

panel of speakers

PARP resistance

combination therapies

replication fork

research

biomarker-driven studies